RiverVest Venture Partners
RiverVest Venture Partners is a leading venture capital firm focused on building life science companies to address significant unmet medical needs. The firm is dedicated to improving the lives of patients, supporting entrepreneurs, and earning the trust of investors through science, strategy, and innovation. With a strong track record of successful investments and exits, RiverVest leverages its expertise to develop biopharma and medical device products that meet high, unmet medical needs, aiming for commercialization or IPO within three to five years of investment.
RiverVest Venture Partners
101 S. Hanley Road, Suite 1850, St. Louis, MO 63105
Portfolio
VentureMed is focused on expanding clinical evidence to drive the growth of its FLEX Vessel Prep™ System.
#Medical Devices
Atalanta Therapeutics closed an oversubscribed $97 million Series B financing to advance RNAi therapies for CNS diseases to clinical trials.
#Biopharmaceuticals
Bluejay Therapeutics received U.S. FDA Breakthrough Therapy Designation for Brelovitug (BJT-778) for the treatment of chronic hepatitis delta.
#Biopharmaceuticals
Amplyx Pharmaceuticals was acquired by Pfizer. Its lead compound, Fosmanogepix (APX001), is under development for the treatment of invasive fungal infections.
#Biopharmaceuticals
Standard Bariatrics entered into a definitive agreement to be acquired by Teleflex Incorporated. The acquisition is expected to accelerate distribution of its Titan SGS stapler for sleeve gastrectomy.
#Medical Devices